Overland Park, Kansas – Hovey Williams LLP, a leading Midwest-based boutique firm specializing in intellectual property law, is pleased to announce another significant victory preserving the integrity of our client’s patents. In a notable achievement, Hovey Williams Partners, Crissa Cook and Scott Brown recently successfully defended client, Ventria Bioscience, Inc. in a second consecutive inter partes review (IPR) challenge to its patents covering recombinant proteins and cell culture media products.

The petition for IPR was first filed by Wuhan Healthgen Biotechnology Corp. in March 2023 alleging that Ventria’s U.S. Patent No. 11,492,389 was invalid.  Wuhan sought to invalidate Ventria’s patent after the International Trade Commission blocked import of certain of its recombinant protein products for infringing another of Ventria’s related patents.  On Monday, October 2, 2023, the Patent Trial and Appeal Board (PTAB) declined to institute inter partes review of the ’389 patent indicating that Wuhan’s challenge was unlikely to succeed on the merits.  This was the second consecutive win following a successful defense of a related patent owned by Ventria last year.

Winning such challenges not once but twice underscores Hovey Williams’ exceptional legal expertise and commitment to protecting our client’s intellectual property rights. This achievement not only reaffirms the validity of Ventria’s patents but also reinforces our reputation as a go-to legal partner for companies facing patent challenges. This triumph is a testament to the diligence and dedication of our legal team and the innovative spirit of Ventria. “We are thrilled to have secured another resounding victory for Ventria, defending their patents for the second time in a row. This victory reaffirms our commitment to protecting our clients’ intellectual property rights and reflects the depth of knowledge and experience within our firm,” Crissa Cook said.